Cover Image
市場調查報告書

Regeneron Pharmaceuticals, Inc.:產品平台分析

Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251712
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
Regeneron Pharmaceuticals, Inc.:產品平台分析 Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月30日 內容資訊: 英文 101 Pages
簡介

Regeneron Pharmaceuticals, Inc.是總公司設置於美國的生物製藥企業,從事治療慢性疾病用醫藥品的藥物研發·開發·製造。產品系列有針對發炎和免疫疾病,骨及軟骨疾病,疼痛,血管系統疾病,癌症及血管新生,眼科疾病,代謝及其相關疾病,肌肉疾病及障礙等各種疾病的治療藥。

本報告提供Regeneron Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Regeneron Pharmaceuticals, Inc. 的基本資料

  • Regeneron Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Regeneron Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Regeneron Pharmaceuticals, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Regeneron Pharmaceuticals, Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 申請登記前的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Regeneron Pharmaceuticals, Inc. :藥物簡介

  • aflibercept (recombinant)
  • alirocumab
  • dupilumab
  • sarilumab
  • ziv-aflibercept (recombinant)
  • evinacumab
  • rinucumab
  • trevogrumab
  • REGN-19081909
  • (aflibercept + nesvacumab)
  • nesvacumab
  • REGN-1154
  • REGN-1193
  • REGN-1400
  • REGN-1979
  • REGN-2222
  • REGN-2810
  • REGN-1001

Regeneron Pharmaceuticals, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Regeneron Pharmaceuticals, Inc. :最新的開發平台資訊

Regeneron Pharmaceuticals, Inc. :開發暫停中的計劃

Regeneron Pharmaceuticals, Inc. :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Regeneron Pharmaceuticals, Inc. :企業理念

Regeneron Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

Regeneron Pharmaceuticals, Inc. :主要的製造設施

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08044CDB

Summary

Global Markets Direct's, 'Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Regeneron Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Regeneron Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Regeneron Pharmaceuticals, Inc.
  • The report provides overview of Regeneron Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Regeneron Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Regeneron Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Regeneron Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Regeneron Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Regeneron Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Regeneron Pharmaceuticals, Inc. Snapshot
  • Regeneron Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Regeneron Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Regeneron Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Regeneron Pharmaceuticals, Inc. - Pipeline Products Glance
    • Regeneron Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Regeneron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Regeneron Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Regeneron Pharmaceuticals, Inc. - Drug Profiles
    • aflibercept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alirocumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarilumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dupilumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • suptavumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fasinumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (aflibercept + nesvacumab)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (aflibercept + rinucumab)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evinacumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trevogrumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ziv-aflibercept (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REGN-19081909
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REGN-1979
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REGN-2810
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Ebola Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Middle East Respiratory Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize GITR for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-L1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REGN-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Blood Cancer and Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Regeneron Pharmaceuticals, Inc. - Pipeline Analysis
    • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Target
    • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Regeneron Pharmaceuticals, Inc. - Dormant Projects
  • Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • crotedumab
      • dapiclermin
      • enoticumab
      • nesvacumab
      • REGN-1400
      • REGN-846
      • rilonacept
      • ziv-aflibercept (recombinant)
  • Regeneron Pharmaceuticals, Inc. - Company Statement
  • Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Regeneron Pharmaceuticals, Inc., Key Information
  • Regeneron Pharmaceuticals, Inc., Key Facts
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Regeneron Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Regeneron Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Regeneron Pharmaceuticals, Inc. - Pre-Registration, 2016
  • Regeneron Pharmaceuticals, Inc. - Phase III, 2016
  • Regeneron Pharmaceuticals, Inc. - Phase II, 2016
  • Regeneron Pharmaceuticals, Inc. - Phase I, 2016
  • Regeneron Pharmaceuticals, Inc. - Preclinical, 2016
  • Regeneron Pharmaceuticals, Inc. - Discovery, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Regeneron Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Regeneron Pharmaceuticals, Inc., Other Locations
  • Regeneron Pharmaceuticals, Inc., Subsidiaries
  • Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities

List of Figures

  • Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2016
  • Regeneron Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top